Some central hypersomnolence syndromes are associated with a positive allosteric modulator of γ-aminobutyric acid (GABA)-A receptors in cerebrospinal fluid. Negative allosteric modulators of GABA-A receptors, including clarithromycin, have been reported to reduce sleepiness in these patients. We sought to systematically assess the effects of clarithromycin on objective vigilance and subjective sleepiness.

Methods

This was a 5-week, randomized, placebo-controlled, double-blind, crossover trial of clarithromycin 500mg with breakfast and lunch, in patients with hypersomnolence syndromes (excluding narcolepsy with cataplexy) and evidence for abnormal cerebrospinal fluid potentiation of GABA-A receptors. The study occurred at a university-affiliated medical center. The primary outcome measure was median reaction time on the psychomotor vigilance task (PVT) at week 2 in each condition. Secondary outcomes included the Epworth Sleepiness Scale, Stanford Sleepiness Scale, Functional Outcomes of Sleep Questionnaire, Pittsburgh Sleep Quality Index, SF-36, and additional PVT measures.

Results

Twenty-three patients began treatment. Three patients dropped out, and final analyses were performed on 20 complete cases. Median reaction time was not significantly different between clarithromycin and placebo. Subjective measures of sleepiness were significantly improved on clarithromycin versus placebo. Altered taste perception occurred, but was the only side effect more common on clarithromycin than placebo. No serious adverse events occurred.

Interpretation

Subjective sleepiness, but not psychomotor vigilance, improved during a 2-week course of clarithromycin. Although additional studies are needed, this suggests that clarithromycin may be a reasonable treatment option in patients with treatment-refractory hypersomnolence. This trial was registered at ClinicalTrials.gov (NCT01146600) and supported by the American Sleep Medicine Foundation. Ann Neurol 2015 Ann Neurol 2015;78:454–465

Supporting Information

References

1Billiard M, Dauvilliers Y. Idiopathic hypersomnia. Sleep Med Rev 2001; 5: 349–358.
10.1053/smrv.2001.0168
CAS PubMed Web of Science® Google Scholar
2Ozaki A, Inoue Y, Hayashida K, et al. Quality of life in patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time: comparison between patients on psychostimulants, drug-naive patients and the general Japanese population. Sleep Med 2012; 13: 200–206.
10.1016/j.sleep.2011.07.014
PubMed Web of Science® Google Scholar
3Ozaki A, Inoue Y, Nakajima T, et al. Health-related quality of life among drug-naive patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time. J Clin Sleep Med 2008; 4: 572–578.
PubMed Web of Science® Google Scholar
4Bayon V, Leger D, Philip P. Socio-professional handicap and accidental risk in patients with hypersomnias of central origin. Sleep Med Rev 2009; 13: 421–426.
10.1016/j.smrv.2009.02.001
PubMed Web of Science® Google Scholar
5Rye DB, Bliwise DL, Parker K, et al. Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors. Sci Transl Med 2012; 4: 161ra51.
10.1126/scitranslmed.3004685
CAS Web of Science® Google Scholar
6Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007; 30: 1705–1711.
10.1093/sleep/30.12.1705
PubMed Web of Science® Google Scholar
7Ali M, Auger RR, Slocumb NL, Morgenthaler T. Idiopathic hypersomnia: clinical features and response to treatment. J Clin Sleep Med 2009; 5: 562–568.
PubMed Web of Science® Google Scholar
8Anderson KN, Pilsworth S, Sharples LD, et al. Idiopathic hypersomnia: a study of 77 cases. Sleep 2007; 30: 1274–1281.
10.1093/sleep/30.10.1274
PubMed Web of Science® Google Scholar
9Wise MS, Arand DL, Auger RR, et al. Treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007; 30: 1712–1727.
10.1093/sleep/30.12.1712
PubMed Web of Science® Google Scholar
10Philip P, Chaufton C, Taillard J, et al. Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial. Sleep 2014; 37: 483–487.
10.5665/sleep.3480
PubMed Web of Science® Google Scholar
11Mayer G, Benes H, Young P, et al. Modafinil in the treatment of idiopathic hypersomnia without long sleep time—a randomized, double-blind, placebo-controlled study. J Sleep Res 2015; 24: 74–81.
10.1111/jsr.12201
PubMed Web of Science® Google Scholar
12Trotti LM, Saini P, Freeman AA, et al. Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: clinical experience. J Psychopharmacol 2013; 28: 697–702.
10.1177/0269881113515062
CAS PubMed Web of Science® Google Scholar
13Heier MS, Evsiukova T, Vilming S, et al. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. Sleep 2007; 30: 969–973.
10.1093/sleep/30.8.969
PubMed Web of Science® Google Scholar
14Trotti LM, Staab BA, Rye DB. Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia. J Clin Sleep Med 2013; 9: 789–795.
10.5664/jcsm.2922
PubMed Web of Science® Google Scholar
15Goldbart A, Peppard P, Finn L, et al. Narcolepsy and predictors of positive MSLTs in the Wisconsin Sleep Cohort. Sleep 2014; 37: 1043–1051.
10.5665/sleep.3758
PubMed Web of Science® Google Scholar
16Vernet C, Arnulf I. Idiopathic hypersomnia with and without long sleep time: a controlled series of 75 patients. Sleep 2009; 32: 753–759.
10.1093/sleep/32.6.753
PubMed Web of Science® Google Scholar
17Pizza F, Moghadam KK, Vandi S, et al. Daytime continuous polysomnography predicts MSLT results in hypersomnias of central origin. J Sleep Res 2013; 22: 32–40.
10.1111/j.1365-2869.2012.01032.x
PubMed Web of Science® Google Scholar
18Dinges DF. Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations. Behav Res Methods Instrum Comput 1985; 17: 652–655.
10.3758/BF03200977
Web of Science® Google Scholar
19Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991; 14: 540–545.
10.1093/sleep/14.6.540
CAS PubMed Web of Science® Google Scholar
20Weaver TE, Laizner AM, Evans LK, et al. An instrument to measure functional status outcomes for disorders of excessive sleepiness. Sleep 1997; 20: 835–843.
CAS PubMed Web of Science® Google Scholar
21Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–483.
Google Scholar
22Hoddes E, Zarcone V, Smythe H, et al. Quantification of sleepiness: a new approach. Psychophysiology 1973; 10: 431–436.
10.1111/j.1469-8986.1973.tb00801.x
CAS PubMed Web of Science® Google Scholar
23Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193–213.
10.1016/0165-1781(89)90047-4
CAS PubMed Web of Science® Google Scholar
24Basner M, Dinges DF. Maximizing sensitivity of the psychomotor vigilance test (PVT) to sleep loss. Sleep 2011; 34: 581–591.
10.1093/sleep/34.5.581
PubMed Web of Science® Google Scholar
25Urbaniak GC, Plous S. Research randomizer (version 4.0) [computer software].
Google Scholar
26Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. Dtsch Arztebl Int 2012; 109: 276–281.
PubMed Web of Science® Google Scholar
27Stevens JP. Intermediate statistics: a modern approach. 3rd ed. New York, NY: Lawrence Erlbaum, 2007.
Google Scholar
28Jones B, Kenward MG. Design and analysis of cross-over trials. 2nd ed. New York, NY: Taylor & Francis, 2003.
10.1201/9781420036091
Google Scholar
29SAS Institute. SAS/STAT user's guide, version 9.3. Cary, NC: SAS Institute, 2011.
Google Scholar
30Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika 1965; 52: 591–611.
10.1093/biomet/52.3-4.591
Web of Science® Google Scholar
31Hartley HO. The maximum F-ratio as a short-cut test for heterogeneity of variance. Biometrika 1950; 37: 308–312.
CAS PubMed Web of Science® Google Scholar
32Cribbie RA, Wilcox RR, Bewell C, Keselman HJ. Tests for treatment group equality when data are nonnormal and heteroscedastic. J Mod Appl Stat Methods 2007; 6: 117–132.
10.22237/jmasm/1177992660
Google Scholar
33Erman MK, Rosenberg R, Modafinil Shift Work Sleep Disorder Study Group. Modafinil for excessive sleepiness associated with chronic shift work sleep disorder: effects on patient functioning and health-related quality of life. Prim Care Companion J Clin Psychiatry 2007; 9: 188–194.
10.4088/PCC.v09n0304
PubMed Google Scholar
34Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997; 49: 444–451.
10.1212/WNL.49.2.444
CAS PubMed Web of Science® Google Scholar
35 Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol 1998; 43: 88–97.
PubMed Google Scholar
36Dauvilliers Y, Bassetti C, Lammers GJ, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol 2013; 12: 1068–1075.
10.1016/S1474-4422(13)70225-4
CAS PubMed Web of Science® Google Scholar
37Beusterien KM, Rogers AE, Walsleben JA, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999; 22: 757–765.
10.1093/sleep/22.6.757
CAS PubMed Web of Science® Google Scholar
38Ho WK, Matthews JN, Henderson R, et al. Dropouts in the AB/BA crossover design. Stat Med 2012; 31: 1675–1687.
10.1002/sim.4497
PubMed Web of Science® Google Scholar
39Baranowski WJ. Clarithromycin-induced hypersomnia in children. Int J Clin Pharmacol Ther 2011; 49: 297–299.
10.5414/CPP49297
CAS PubMed Web of Science® Google Scholar
40Rezvanian E, Watson NF. Kleine-Levin syndrome treated with clarithromycin. J Clin Sleep Med 2013; 9: 1211–1212.
PubMed Web of Science® Google Scholar
41Demartini G, Esposti D, Marthyn P, et al. Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFNgamma and IL-10 plasma levels in patients with community acquired pneumonia. J Chemother 2004; 16: 82–85.
10.1179/joc.2004.16.1.82
CAS PubMed Web of Science® Google Scholar
42Vgontzas AN, Pejovic S, Zoumakis E, et al. Daytime napping after a night of sleep loss decreases sleepiness, improves performance, and causes beneficial changes in cortisol and interleukin-6 secretion. Am J Physiol Endocrinol Metab 2007; 292: E253–E261.
10.1152/ajpendo.00651.2005
CAS PubMed Web of Science® Google Scholar
43Gonzalez A, Stombaugh J, Lozupone C, et al. The mind-body-microbial continuum. Dialogues Clin Neurosci 2011; 13: 55–62.
PubMed Google Scholar
44Jakobsson HE, Jernberg C, Andersson AF, et al. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One 2010; 5: e9836.
10.1371/journal.pone.0009836
CAS PubMed Web of Science® Google Scholar
45Edlund C, Beyer G, Hiemer-Bau M, et al. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis 2000; 32: 81–85.
10.1080/00365540050164272
CAS PubMed Web of Science® Google Scholar
46US Food and Drug Administration. Clarithromycin prescribing information. 2013. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050662s052lbl.pdf. Accessed January 28, 2015.
Google Scholar
47US Food and Drug Administration. Modafinil FDA approved labeling. 2007. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020717s020s013s018lbl.pdf. Accessed January 28, 2015.
Google Scholar
48US Food and Drug Administration. Armodafinil prescribing information. 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021875s005s008s015lbl.pdf. Accessed January 28, 2015.
Google Scholar
49Trotti LM, Saini P, Freeman AA, et al. Clarithromycin for the treatment of hypersomnia: a randomized, double-blind, placebo-controlled crossover trial. Sleep 2013; 36: A248.
Google Scholar

Citing Literature

Volume78, Issue3

September 2015

Pages 454-465

Clarithromycin in γ-aminobutyric acid–Related hypersomnolence: A randomized, crossover trial

Abstract

Objective

Methods

Results

Interpretation

Supporting Information

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley